Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Biotech Business
OXiGENE Appoints Chief Business Officer and Head of Business Development, John A. Kollins
March 12th, 2007
OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-stage biotechnology company developing novel therapeutics to treat cancer and eye diseases, announced that John A. Kollins has joined the Company as Senior Vice President and Chief Business Officer. Mr. Kollins brings with him a proven track record of completing major in-licensing and out-licensing transactions. As Chief Business Officer for OXiGENE, Mr. Kollins will be responsible for all business development activities as well as commercial strategy for OXiGENE. "We are thrilled to have John join us," commented Richard Chin, President and Chief Executive Officer for OXiGENE. "We believe that, by hiring someone of...
Source: Pharma Business Week (2007-03-12)
|
